IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. ...
예상 EPS $0.55 · 매출 $23.20M · 1 명의 애널리스트
예상 EPS $0.61 · 매출 $25.60M · 2 명의 애널리스트
예상 EPS $2.09 · 매출 $91.20M · 1 명의 애널리스트
예상 EPS $0.59 · 매출 $25.00M · 1 명의 애널리스트
$0.77 주당
$0.77 주당
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $83.8M | +14.4% | -6.9% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $22.5M | +16.9% | -10.3% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +76.7% | -0.2% | -3.2% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | +31.2% | +4.0% | -5.2% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | +26.8% | +2.1% | -3.7% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $17.2M | -2.5% | -27.0% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | +20.5% | -14.8% | -21.6% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 0.0% | -100.0% | — |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 7.98x | -9.8% | +32.7% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $108.8M | +10.6% | +0.5% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | 1.75 vs 1.86 | -6.2% | 0.41 vs 0.44 | -6.8% |
| 매출 서프라이즈 | $83.8M vs $82.7M | +1.3% | $20.5M vs $20.4M | +0.6% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Jun 20, 2026 | GLENN JOHN | officer: CFO | Common Stock | A | 5,796 | — |
| Jun 20, 2026 | GLENN JOHN | officer: CFO | Common Stock | D | 2,319 | $92.20 |
| Jun 20, 2026 | GLENN JOHN | officer: CFO | Restricted Stock Units | D | 5,796 | — |
| Jun 4, 2026 | Scharen-Guivel Hilda Frederique | director | Common Stock | D | 1,766 | $95.00 |
| Jun 4, 2026 | Scharen-Guivel Hilda Frederique | director | Common Stock | D | 1,234 | $95.00 |
Operator: Hello, and welcome to the IRadimed Corporation's Second Quarter of 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, July 31, 2026, and contains time-sensitive accurate information that is valid only for today. Earlier IRadimed released its financial results for the second quarter of 2026. A copy of this press release announcing the company's earnings is available under the headings News on their website at iradimed.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live on the company's website at iradimed.com, and a replay will be available there for the next 90 days. Some of the information in today's section will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans and events and may include the company's expected future results. IRadimed reminds you that future results may differ materially from these forward-looking statements due to severe risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section in the company's most recent report filed with the Securities and Exchange Commission, which may obtain free from the SEC's website at sec.gov. I want to turn the call over to Roger Susi, President and Chief Executive Officer of IRadimed Corporation. Mr. Susi? Roger Susi: Thank you, operator. Good morning, and welcome to IRadimed Corp's Second Quarter 2026 Earnings Call. This quarter, we embarked on the first general release production of the new 3870 MR IV pump system as planned, targeting, as discussed last quarter, the building of 130 to 135 of these new pumps. I'm very pleased to report that our teams performed exceptionally well and achieved our manufacturing target, no small task. Taking 3870 production from a standing start to an impressive rate in the quarter. Those efforts with those efforts, we were able to achieve revenue and earnings per our guidance with revenue of $20.5 million and earnings of $0.41 on a GAAP basis and non-GAAP earnings of $0.46 per share. As we expected and guided. The new pump launch consumes significant effort, including increased labor and overhead expenses, much of which is reflected in the quarter's gross margin of 74%. I want to speak to what's next, and that starts with a discussion of how bookings were in the quarter, how fast we can continue to ramp the new 3870 pump production and a short recap of our opportunity. Opportunities for the new 3870 pump system are both the increased penetration of the greenfield which are predominantly those facilities that continue to deal with IV fluid delivery in the MR setting via the various old school workarounds, expansion of current customer use requiring more pumps, as well as …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Roger E. Susi | Founder, Chairman, Chief Executive Officer & President | USD 780,598 | Male | 1953 | Active |
John F. Glenn | Chief Financial Officer & Corporate Secretary | USD 609,994 | Male | 1962 | Active |
Jeff Chiprin | Chief Commercial Officer | USD 529,360 | Male | 1966 | Active |
Randy Waddell | Vice President of Worldwide Sales & Marketing | USD 446,151 | Male | — | Active |
Lynn Neuhardt | Vice President of Research & Development | USD 354,946 | Male | — | Active |
Chris Williamson | Executive Vice President of Continuous Improvement & Information Technology | — | Male | — | Active |
Matt Garner | Controller | — | Male | — | Active |
Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider's stock after selling 15,062 shares during the period. Algert Global
Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong
iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.
